newsfilter
← Latest News
GlobeNewswire·

Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy

  • Longeveron Inc. received a USPTO patent for administering isolated allogeneic mesenchymal stem cells to female patients with sexual dysfunction to improve sexual quality of life.
  • U.S. Patent No. 12,496,316 grants rights in the United States through 2038, with potential for term or regulatory exclusivity extensions.
  • Female sexual dysfunction affects up to 46% of women, is common with advancing age, and currently has few treatment options.
  • Longeveron plans to enter licensing or partnering agreements for the development and commercialization of this stem cell therapy.
  • The company's lead product, laromestrocel (LOMECEL-B), is derived from bone marrow of young healthy adult donors and targets regenerative needs.
  • Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome, Alzheimer's disease, and Pediatric Dilated Cardiomyopathy.